According to the company, these funds will be used to accelerate the international expansion of its first product AcuPebble SA100 and support its ambition to become the preferred solution for home sleep testing worldwide.
The investment was led by Kibo Ventures, along with Mundi Ventures, Kindred Capital, and Comprador Holdings among others.
Acurable's first product, the AcuPebble SA100, has been developed to simplify obstructive sleep apnoea (OSA) detection and monitoring by enabling fully automated testing of patients at home for the first time. After successfully launching AcuPebble SA100 in the UK and Spain in 2021, Acurable is now looking to scale up in these two countries and expand into further European markets and North America.
AcuPebble SA100 is the first wearable medical device to obtain a CE mark in Europe for the automated diagnosis of obstructive sleep apnoea at home and has received FDA 510(k) clearance in the US. It is also the first device in the world that achieves the accuracy in likelihood ratios required by the US Agency for Healthcare Research and Quality (AHRQ) to consider a diagnostic method equivalent to the gold standard.
This funding follows the recent announcement of a strategic distribution agreement with Nyxoah to provide the AcuPebble SA100 home sleep test to the German market.
Acurable's international expansion brings it one step closer to solving the current unmet needs in diagnosis and monitoring of OSA - a significant issue that is said to affect approximately one billion people globally.
Professor Esther Rodriguez-Villegas, inventor of the AcuPebble technology, co-CEO and founder of Acurable commented, “The response to AcuPebble SA100 since its launch has been incredible, and we are thrilled to see the product being used to help patients and clinicians in the real world. This funding will help us reach our initial goal of diagnosing one million patients and gives us the opportunity to continue working on new products that will fundamentally improve the lives of millions of people living with severe chronic conditions.”
Based on contact acoustic sensing, AcuPebble technology can automatically extract a wide range of cardio-respiratory disease-related physiological markers. It does this non-invasively and continuously with accuracy comparable to current complex gold-standard methods, which rely heavily on clinical human resources.
The technology is positioned to play a significant role in improving the diagnosis and management of some of the most significant chronic respiratory and cardiovascular conditions today.
